238 related articles for article (PubMed ID: 26942887)
41. A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression.
Zhang W; Liu S; Liu K; Wang Y; Ji B; Zhang X; Liu Y
J Int Med Res; 2014 Jun; 42(3):611-8. PubMed ID: 24670536
[TBL] [Abstract][Full Text] [Related]
42. ADAM10-Interacting Tetraspanins Tspan5 and Tspan17 Regulate VE-Cadherin Expression and Promote T Lymphocyte Transmigration.
Reyat JS; Chimen M; Noy PJ; Szyroka J; Rainger GE; Tomlinson MG
J Immunol; 2017 Jul; 199(2):666-676. PubMed ID: 28600292
[TBL] [Abstract][Full Text] [Related]
43. The Gut-Brain Axis in Autism Spectrum Disorder: A Focus on the Metalloproteases ADAM10 and ADAM17.
Zheng Y; Verhoeff TA; Perez Pardo P; Garssen J; Kraneveld AD
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374371
[TBL] [Abstract][Full Text] [Related]
44. ADAM10 Cell Surface Expression but Not Activity Is Critical for Staphylococcus aureus α-Hemolysin-Mediated Activation of the NLRP3 Inflammasome in Human Monocytes.
Ezekwe EA; Weng C; Duncan JA
Toxins (Basel); 2016 Mar; 8(4):95. PubMed ID: 27043625
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
Shackleton B; Crawford F; Bachmeier C
Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
[TBL] [Abstract][Full Text] [Related]
46. Activation of peroxisome proliferator-activated receptor α stimulates ADAM10-mediated proteolysis of APP.
Corbett GT; Gonzalez FJ; Pahan K
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8445-50. PubMed ID: 26080426
[TBL] [Abstract][Full Text] [Related]
47. Targeting ADAM10 in Renal Diseases.
Wang JN; Cao XJ
Curr Mol Med; 2023; 23(10):1037-1045. PubMed ID: 36278450
[TBL] [Abstract][Full Text] [Related]
48. The Cxadr-Adam10 complex plays pivotal roles in tight junction integrity and early trophoblast development in mice.
Jeong Y; Ock SA; Yoo JG; Yu DY; Choi I
Mol Reprod Dev; 2019 Nov; 86(11):1628-1638. PubMed ID: 31373105
[TBL] [Abstract][Full Text] [Related]
49. New insights into the tetraspanin Tspan5 using novel monoclonal antibodies.
Saint-Pol J; Billard M; Dornier E; Eschenbrenner E; Danglot L; Boucheix C; Charrin S; Rubinstein E
J Biol Chem; 2017 Jun; 292(23):9551-9566. PubMed ID: 28428248
[TBL] [Abstract][Full Text] [Related]
50. Expression of ADAM17 and ADAM10 in nasal polyps.
Bae WY; Park SK; Kim do H; Koh TK; Hur DY; Chueh HW
Int Forum Allergy Rhinol; 2016 Jul; 6(7):731-6. PubMed ID: 27012683
[TBL] [Abstract][Full Text] [Related]
51. Adam10 mediates the choice between principal cells and intercalated cells in the kidney.
Guo Q; Wang Y; Tripathi P; Manda KR; Mukherjee M; Chaklader M; Austin PF; Surendran K; Chen F
J Am Soc Nephrol; 2015 Jan; 26(1):149-59. PubMed ID: 24904084
[TBL] [Abstract][Full Text] [Related]
52. Canonical Notch2 signaling determines biliary cell fates of embryonic hepatoblasts and adult hepatocytes independent of Hes1.
Jeliazkova P; Jörs S; Lee M; Zimber-Strobl U; Ferrer J; Schmid RM; Siveke JT; Geisler F
Hepatology; 2013 Jun; 57(6):2469-79. PubMed ID: 23315998
[TBL] [Abstract][Full Text] [Related]
53. TLR4-mediated galectin-1 production triggers epithelial-mesenchymal transition in colon cancer cells through ADAM10- and ADAM17-associated lactate production.
Park GB; Kim D
Mol Cell Biochem; 2017 Jan; 425(1-2):191-202. PubMed ID: 27837433
[TBL] [Abstract][Full Text] [Related]
54. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer.
Mueller AC; Piper M; Goodspeed A; Bhuvane S; Williams JS; Bhatia S; Phan AV; Van Court B; Zolman KL; Peña B; Oweida AJ; Zakem S; Meguid C; Knitz MW; Darragh L; Bickett TE; Gadwa J; Mestroni L; Taylor MRG; Jordan KR; Dempsey P; Lucia MS; McCarter MD; Del Chiaro M; Messersmith WA; Schulick RD; Goodman KA; Gough MJ; Greene CS; Costello JC; Neto AG; Lagares D; Hansen KC; Van Bokhoven A; Karam SD
Cancer Res; 2021 Jun; 81(12):3255-3269. PubMed ID: 33526513
[TBL] [Abstract][Full Text] [Related]
55. Effect of a dominant-negative form of ADAM10 in a mouse model of Alzheimer's disease.
Schroeder A; Fahrenholz F; Schmitt U
J Alzheimers Dis; 2009; 16(2):309-14. PubMed ID: 19221420
[TBL] [Abstract][Full Text] [Related]
56. Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice.
Geisler F; Nagl F; Mazur PK; Lee M; Zimber-Strobl U; Strobl LJ; Radtke F; Schmid RM; Siveke JT
Hepatology; 2008 Aug; 48(2):607-16. PubMed ID: 18666240
[TBL] [Abstract][Full Text] [Related]
57. ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis.
Caolo V; Swennen G; Chalaris A; Wagenaar A; Verbruggen S; Rose-John S; Molin DG; Vooijs M; Post MJ
Angiogenesis; 2015 Jan; 18(1):13-22. PubMed ID: 25218057
[TBL] [Abstract][Full Text] [Related]
58. Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling.
Woods N; Trevino J; Coppola D; Chellappan S; Yang S; Padmanabhan J
Oncotarget; 2015 Nov; 6(34):35931-48. PubMed ID: 26440150
[TBL] [Abstract][Full Text] [Related]
59. Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells.
Liu S; Zhang W; Liu K; Ji B; Wang G
Mol Med Rep; 2015 Jan; 11(1):597-602. PubMed ID: 25323956
[TBL] [Abstract][Full Text] [Related]
60. Soluble T cell immunoglobulin and mucin domain (TIM)-1 and -4 generated by A Disintegrin And Metalloprotease (ADAM)-10 and -17 bind to phosphatidylserine.
Schweigert O; Dewitz C; Möller-Hackbarth K; Trad A; Garbers C; Rose-John S; Scheller J
Biochim Biophys Acta; 2014 Feb; 1843(2):275-87. PubMed ID: 24286866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
